Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
59 hedge funds and large institutions have $29.6M invested in Aralez Pharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.
38% more capital invested
Capital invested by funds: $21.5M → $29.6M (+$8.12M)
21% more call options, than puts
Call options by funds: $386K | Put options by funds: $320K
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
18% less funds holding
Funds holding: 72 → 59 (-13)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
+$230K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$152K |
| 3 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
+$66.9K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$51.3K |
| 5 |
VF
Virtu Financial
New York
|
+$39.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$2.75M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$360K |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$270K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$146K |
| 5 |
SCA
Salient Capital Advisors
Houston,
Texas
|
-$135K |
ARLZ Hedge Fund Activity: Q3 2017 in Review
59 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q3 2017, worth a combined $29.6M — up 38% from $21.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ARLZ and 6 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Brown Advisory Securities, opening a new position worth an estimated $230K. The largest seller was Broadfin Capital, exiting entirely with an estimated $2.75M sold.
- 59 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q3 2017, down from 72 in Q2 2017.
- Funds reported $29.6M of Aralez Pharmaceuticals Inc. stock for Q3 2017, up 38% quarter-over-quarter.
- 6 funds opened new Aralez Pharmaceuticals Inc. positions in Q3 2017 and 16 closed out, a net change of -10 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q3 2017 was Brown Advisory Securities, an estimated $230K added.
- The largest Aralez Pharmaceuticals Inc. seller in Q3 2017 was Broadfin Capital, an estimated $2.75M sold.
Based on aggregated 13F filings for Q3 2017.